<img src="https://ml.globenewswire.com/Resource/Download/a84ce25b-a774-4635-9b79-d45241f5decc?size=2" nborder="0" align="left" hspace="5" vspace="5" title="Cellectis Logo.png" alt="Cellectis Inc."/>NEW YORK, Sept. 11, 2026 <a href="https://www.globenewswire.com" target="_blank">(GLOBE NEWSWIRE)</a> -- <a href="https://www.globenewswire.com/Tracker?data=Oe52355Da9BuAmTsTnbNRwDT1TKv94F3leCm_zegrj3FSH5mmmINrWlD1gbBnjeOE2h3o50vCHCy-9pXmhFORQ==" rel="nofollow" target="_blank" title="Cellectis">Cellectis</a> (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene editing platform to develop life-saving cell and gene therapies, today announced that it will host a conference call and webcast on Monday, September 14, 2026 to provide a business update. Conference Call and Webcast Details: September 14, 2026 <ul type="disc"><li style="text-align:justify;">English-language at 8:00 a.m. ET. / 2:00 p.m. CET</li></ul> Webcast link: <a href="https://www.globenewswire.com/Tracker?data=3EHHLKk19HxblUHULOI89IQGUQqGoIj9Fbaz1qQPuiIGw3jc0rEZwOWKDRuswAn9vnQ_k1s0lnYsJlDNujSuJ33I9lk_bJfk2u4V53Qf3CPLC81nGT3pdHUtEB3WO5Gd5BpcM9AhAwLthKNI_dxPS3xGjTXtFG0D1_-y3FyHSRvK-3JSAyBN2ctQaghUVNEt3oMWO18WuBHiXXwoqxbq4QXL13L2Qi2k_IIcyZ8lzZqTwStZ0JTW6Di-v1__3Hjrf6I0jqsRX8X3MXpM7yl99EM2Yr0S6zswxGqx3SQYrGzxS03Wv4cdh0ElIMrYMhAFlmW985nCqpuLIzEE4GCksyjvJoLsoKCUgwM3rl2QHQxCRUSPvGsmOl7pu6aJnG7LTCxQqx2OAx-0LKIFa2aVqvBlwGPsZMoHo2Q1tdlnxf7UL6_wxK2j1ClFa0mGE2aBF_0obdnQWWj9IvmSJbW8SwxydG4mTxmwr9KtDymTyst6sMM7MD_Jut5aUdy95xbvFy2fnpQpZYDYomMRbJYp8pdQSjFen1qm22PqH6DVyNYcvVjcfl1OTp0_YA2-QqEIe5ehI6nQXH8hz9NHkMcGKfYdXu3VU446V2GJ9p9GBXXjRT6ATUo_7pdQcmQPton2TauNMtTe8yoJtTYHmPlTUiw5eoyO9s5twFYtXibAtxn1ZQUuICipki8PlnKjVUaJoPqEbeDVtkj1yOlePoEW23JsZvGMCd_iCS7CjlSK1Xmyi8RHw33jSc5D5V7aF-EZxhkbgK7eImYEyrbBufvVRg==" rel="nofollow" target="_blank" title="">https://viavid.webcasts.com/starthere.jsp?ei=1775356&amp;tp_key=7d1d05c480</a> Phone number: +1 (800) 717 1738 or +1 (646) 307 1865 France Toll Free: +33 (800) 945 120 <ul type="disc"><li style="text-align:justify;">French-language at 9:00 a.m. ET. / 3:00 p.m. CET</li></ul> Webcast link: <a href="https://www.globenewswire.com/Tracker?data=3EHHLKk19HxblUHULOI89IQGUQqGoIj9Fbaz1qQPuiIGw3jc0rEZwOWKDRuswAn9fT9BcQzxi8sGU_MXwP5KOuKQFcjmTA1igaQCcGig2q77eZquOlG5oP-qXJkPBDFPClo_5V5joxsfMT14lP-tHZr7v2L-rv831fcKQZ_HolDyv2KblEf6Z4gMOeg049aWiT6WOOC9qTi7S3Phlxfqraf1YpcCF2LbKP9Q5W1EX8E=" rel="nofollow" target="_blank" title="">https://viavid.webcasts.com/starthere.jsp?ei=1775361&amp;tp_key=2968b7b0ca</a> Phone number: +1 (800) 717 1738 or +1 (646) 307 1865 France Toll Free: +33 (800) 945 120 A replay will be available on the <a href="https://www.globenewswire.com/Tracker?data=KXA_bJ0bdLsaVA5zFNGZFCDuqWygq-nEBfGwztRHVUMBcHApSV5LiQMSzRV8-gHknZtLKMCllU5F8iwhnDXie9EAE0sdtLgTkIvkkvynyf5rFzY8VnXnp5jWCGXeQw5sqcmNVqXrl7ej_iS2fzyULg==" rel="nofollow" target="_blank" title="">Company’s website</a> following the event.   About Cellectis      Cellectis is a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies. The company utilizes an allogeneic approach for CAR T immunotherapies in oncology, pioneering the concept of off-the-shelf and ready-to-use gene-edited CAR T-cells to treat cancer patients, and a platform to develop gene therapies in other therapeutic indications. With its in-house manufacturing capabilities, Cellectis is one of the few end-to-end gene editing companies that controls the cell and gene therapy value chain from start to finish. Cellectis’ headquarters are in Paris, France, with locations in New York and Raleigh, NC. Cellectis is listed on the Nasdaq Global Market (ticker: CLLS) and on Euronext Growth (ticker: ALCLS). To find out more, visit <a href="https://www.globenewswire.com/Tracker?data=xvf-n5aOO0toKOiRPlMKLpC8YyF7Gp8nrQdBNxBWVQqF5R-3PCOs3IOA3-bQQFGHGqP6j4-lXbiwX52E7Ve3K4H3YSb-OGErPm3knLs__LQ=" rel="nofollow" target="_blank" title="">www.cellectis.com</a> and follow Cellectis on <a href="https://www.globenewswire.com/Tracker?data=CqzXDuQK-ohbfht7mGQC1im5Hk_lJ6geNuvbvV5Sna6w96WbJ1kQO7M3OvlC3l0ZSgFXugOBTmncppHWl8klQ7nqFzgfWT3D37NFrJAnB6R7xzVaAJQyUM_JtMqYqM9T" rel="nofollow" target="_blank" title="LinkedIn">LinkedIn</a> and <a href="https://www.globenewswire.com/Tracker?data=tw6zDfIFdH9fet-Q2zwdv48UL1YW8bmP17WrNrxlLwNKF2q_PgTZnTX_CgCaTCzFeeIJp_Di1ET_hkKAI1x1rw==" rel="nofollow" target="_blank" title="X">X</a>.   For further information on Cellectis, please contact:                Media contacts:               Pascalyne Wilson, Director, Communications, + 33 (0)7 76 99 14 33,  Patricia Sosa Navarro, Chief of Staff to the CEO, +33 (0)7 76 77 46 93, <a href="https://www.globenewswire.com/Tracker?data=B3j389u9NImYe2OzIPAOLDmhbEF_JqXdFo4cVhw-fWcGeDIcx-2CyPljJcCamMN0ElLTuxlL4Z2DvyUC33807YYGU1rwzycny9oUxI_NCqs=" rel="nofollow" target="_blank" title="media@cellectis.com">media@cellectis.com</a> Investor Relations contact:            Arthur Stril, Chief Financial Officer &amp; Chief Business Officer, <a href="https://www.globenewswire.com/Tracker?data=CSoNvzmpkprSFAzZkTfS5Dn9BDE_w4S2z_EGIg4XHrvKGE1y2_GJuFtnXXJ6jWPWnmTwfLngxmIeL6bY89WvgZ4c_LwCThkUsFGJCSqrjVA=" rel="nofollow" target="_blank" title="investors@cellectis.com">investors@cellectis.com</a> Attachment <ul id="gnw_attachments_section-items"><li><a href="https://www.globenewswire.com/Tracker?data=cHpIqlakBp1x1pdHQemDe57p7itp-0es-luh4nsfV38J-xgb9EZo78Zi4q7ZlLkq6akhCaSRWGVDet74uA5QWaylRD2_8Wra1vQ-C9aDKNE2VSTIaFRZkVrljC_emglVnyL40WTTFY8AGT4EOjrhvvxx73aHFAV1kBp81N-6JbPbSe1GAGoKnv-h0eYT-JkP" rel="nofollow" target="_blank" title="PRESS RELEASE_conference call_ENGLISH">PRESS RELEASE_conference call_ENGLISH</a></li></ul> <img alt="" src='https://ml.globenewswire.com/media/ZWZjMjE3OWQtMzc1My00MTljLThhYWYtNDExYTdiYTZhNGU0LTEwNjE0NDgtMjAyNi0wOS0xMS1lbg==/tiny/Cellectis-Inc-.png' referrerpolicy='no-referrer-when-downgrade' />

Cellectis to Host Conference Call and Webcast on September 14 to Provide a Business Update

Latest news from the world of business and finance – both local and global

MONEY FM 89.3 is Singapore's first and only Business and Personal Finance station, featuring local and international business and financial news.

MONEY FM 89.3

Discover newsletters from our DJs on LinkedIn